Serum lipid levels during carbamazepine medication. A prospective study

J. I. Isojarvi, A. J. Pakarinen and V. V. Myllyla
Department of Neurology, University of Oulu, Finland.

OBJECTIVE--The aim of the study was to evaluate serum lipid levels during carbamazepine medication. DESIGN--A 5-year prospective follow-up study. SETTING--Outpatient department, University Central Hospital of Oulu (Finland). PATIENTS--Thirty-six consecutive untreated patients with recently diagnosed idiopathic epilepsy. All patients completed the 1-year follow-up, and 19 patients completed the 5-year follow-up. INTERVENTIONS--The patients were treated with carbamazepine for their newly diagnosed seizure disorder. MAIN OUTCOME MEASURES--Serum lipid levels were followed up during the medication use. RESULTS--Serum total cholesterol and high-density lipoprotein cholesterol concentrations increased after 2 months of treatment with carbamazepine and remained high after 1 and 5 years. Furthermore, concentrations of serum low-density lipoprotein cholesterol and triglycerides increased transiently during the first year of medication. The increase in serum total cholesterol levels correlated with an increase in serum gamma-glutamyltransferase concentrations. CONCLUSIONS--Serum lipid levels change during carbamazepine medication; the increase in serum concentrations of total cholesterol and high-density lipoprotein cholesterol seems permanent, but the increase in serum low-density lipoprotein cholesterol and triglyceride levels is transient. The change in lipid metabolism may be associated with induction of the liver enzymes during carbamazepine medication. The increase in serum cholesterol and high-density lipoprotein cholesterol levels may have clinical relevance with regard to the incidence of atherosclerosis and coronary heart disease in patients with epilepsy receiving carbamazepine medication.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Lipid Profile, Apolipoproteins A and B in Children With Epilepsy
Tomoum et al.
J Child Neurol 2008;23:1275-1281.
ABSTRACT  

Evolution of Serum Lipids and Lipoprotein (a) Levels in Epileptic Children Treated With Carbamazepine, Valproic Acid, and Phenobarbital
Castro-Gago et al.
J Child Neurol 2006;21:48-53.
ABSTRACT  

Possible Induction of Cholinesterase in Epileptic Patients Treated With Anticonvulsant Drugs: Relationship With Lipoprotein Levels
Tutor-Crespo et al.
J Clin Pharmacol 2004;44:974-980.
ABSTRACT | FULL TEXT  

Fasting serum insulin and lipid levels in men with epilepsy
Pylvanen et al.
Neurology 2003;60:571-574.
ABSTRACT | FULL TEXT  

Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults
Bramswig et al.
Am. J. Physiol. Heart Circ. Physiol. 2002;282:H704-H716.
ABSTRACT | FULL TEXT  

Effect of Antiepileptic Drugs on Plasma Lipoprotein (a) and Other Lipid Levels in Childhood
Mujgan Aynaci et al.
J Child Neurol 2001;16:367-369.
ABSTRACT  

Oxcarbazepine Versus Carbamazepine Treatment and Induction of Serum Lipid Abnormalities
Papacostas
J Child Neurol 2000;15:138-140.
ABSTRACT  

NALTREXONE EXERTS A FAVOURABLE EFFECT ON PLASMA LIPIDS IN ABSTINENT PATIENTS WITH ALCOHOL DEPENDENCE
Budzynski et al.
Alcohol Alcohol 2000;35:91-97.
ABSTRACT | FULL TEXT